[1] |
McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma[J]. Hepatology, 2021, 73:4-13.
|
[2] |
孙全鹏, 樊超, 展德玺, 等. 罗哌卡因抑制人肝癌细胞系Hep3B增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42:448-453.
|
[3] |
Gao ZX, Zhang ZS, Qin J, et al. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma[J]. Phytomedicine, 2023, 112:1-15.
|
[4] |
Chibaya L, Karim B, Zhang H, et al. Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis[J]. Proc Natl Acad Sci U S A, 2021, 118:1-12.
|
[5] |
羊丹, 徐菁, 陈保银, 等. 长链非编码RNA DDX11-AS1对肝癌细胞增殖、侵袭能力的影响及其机制[J]. 山东医药, 2021, 61:11-14.
|
[6] |
黄驿胜,叶启文,王竞枫. miR-203a-3p抑制人肝癌细胞系增殖[J]. 基础医学与临床, 2023, 43:87-94.
|
[7] |
Zeng X, Guo F, Ouyang D. A review of the pharmacology and toxicology of aucubin[J]. Fitoterapia, 2020, 140:1-11.
|
[8] |
Zeng X, Zhou J, Xiong Z, et al. Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis[J]. Cell Mol Immunol, 2021, 18:1005-1015.
|
[9] |
Chan CY, Yuen VW, Chiu DK, et al. Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity[J]. Hepatology, 2023, 77:729-744.
|
[10] |
Miao R, Fang X, Wei J, et al. Akt: a potential drug target for metabolic syndrome[J]. Front Physiol, 2022, 13:1-10.
|
[11] |
Tsai PJ, Lai YH, Manne RK, et al. Akt: a key transducer in cancer[J]. J Biomed Sci, 2022, 29:1-17.
|
[12] |
Iida M, Harari PM, Wheeler DL, et al. Targeting AKT/PKB to improve treatment outcomes for solid tumors[J]. Mutat Res, 2020, 819-820:1-28.
|
[13] |
Zafar A, Khan MJ, Naeem A. MDM2- an indispensable player in tumorigenesis[J]. Mol Biol Rep, 2023, 50:6871-6883.
|
[14] |
Koo N, Sharma AK, Narayan S. Therapeutics targeting p53-MDM2 interaction to induce cancer cell death[J]. Int J Mol Sci, 2022, 23:1-21.
|
[15] |
Ayesha M, Majid A, Zhao D, et al. miR-4521 plays a tumor repressive role in growth and metastasis of hepatocarcinoma cells by suppressing phosphorylation of FAK/AKT pathway via targeting FAM129A[J]. J Adv Res, 2021, 36:147-161.
|